The Canadian COVID‑19 Funded Research Database

University of British Columbia

Algonquin College
Ambrose University
Association for Canadian Studies
Athabasca University
Aurora College

B.C. Centre for Disease Control
B.C. Centre for Excellence in HIV/AIDS
B.C. Children's Hospital
B.C. Women's Hospital
Bishop's University
Brandon University
British Columbia Centre on Substance Use
Brock University
Bruyère Research Institute

Dalhousie University
Dawson College
Durham College

École de technologie supérieure
École nationale d'administration publique
École Polytechnique de Montréal
Emily Carr University of Art and Design

Fanshawe College
First Nations Health Authority
Fleming College

Georgian College
Grant MacEwan University

HEC Montréal
Hospital for Sick Children
Humber College
Huron University College

Indigenous Diabetes Health Circle
INRS
Institut de recherches cliniques de Montréal
Institut de tourisme et d'hôtellerie du Québec
Institut national de la recherche scientifique
Institut national de santé publique du Québec
Institute for Work & Health
IWK Health Centre

John Abbott College
Justice Institute of British Columbia

Keenan Research Centre
King's University College at Western University
Kwantlen Polytechnic University

MacEwan University (Grant MacEwan University)
McGill University
McMaster University
Memorial University of Newfoundland
Métis Nation of Ontario
Mount Royal University
Mount Saint Vincent University
Moyo Health and Community Services

Native Women's Association of Canada
North Island College
North York General Hospital
Northern Ontario School of Medicine
Nova Scotia Health Authority

OCAD University
Ontario Centre of Excellence for Child and Youth Mental Health
Ontario Institute for Cancer Research
Ontario Tech University
Ontario Tech University (University of Ontario Institute of Technology)
Ottawa Heart Institute Research Corporation
Ottawa Hospital Research Institute

Princess Margaret Cancer Centre

Québec à Chicoutimi
Québec à Montréal
Québec à Rimouski
Québec à Trois-Rivières
Queen's University

Royal Alexandra Hospital
Royal Roads University
Ryerson University

TÉLUQ
The University of Calgary
The University of Regina
Thompson Rivers University
Toronto General Research Institute
Trent University
Trillium Health Partners

Vancouver Island University

Western University
Western University (The University of Western Ontario)
Wilfrid Laurier University
Women's College Hospital

York University
Yukon University

Back to main page

Displaying 21 through 30 of 43 results (Download Results)

Show results per page

All-cause and cause-specific acute morbidity attributable to Covid-19 epidemic, severe Covid-19 symptoms, and adverse birth outcomes in Canada.

Lisonkova, Sarka | University of British Columbia | Project Grant | $168,300

CIHR British Columbia 2021

COVID-19 Variant Supplement – Neutralizing human-derived single-chain antibodies against SARS-CoV-2

Bach, Horacio | University of British Columbia | Operating Grant | $50,000

CIHR British Columbia 2021

COVID-19 Variant Network – Bespoke transition state analog inhibitors of SARS-CoV-2 3CL and PL proteases

Strynadka, Natalie C | University of British Columbia | Operating Grant | $100,000

CIHR British Columbia 2021

CATCO Scale-Up COVID‑19 Supplement – Canadian Treatments for COVID-19: SOLIDARITY

Murthy, Srinivas | University of British Columbia | Operating Grant | $3,500,000

CIHR British Columbia 2021

COVID-19 Variant Supplement – Assessing the impact of the COVID‑19 pandemic on social and health outcomes among young people: A mixed-method comparative analysis in Canada and France

Knight, Rodney E | University of British Columbia | Operating Grant | $50,000

CIHR British Columbia 2021

Upstream determinants of effective COVID‑19 response: tools development and application through a case study in British Columbia

Berman, Peter | University of British Columbia | Project Grant | $118,575

CIHR British Columbia 2021

Enhancing culturally-safe ways for community wholistic health and wellness aspirations during COVID-19.

Warburton, Darren E | University of British Columbia | Other | $99,324

CIHR British Columbia 2021

COVID-19 Variant Supplement – Peptide macrocycle decoys against COVID‑19 viral spike protein

Perrin, David M | University of British Columbia | Operating Grant | $50,000

CIHR British Columbia 2021

Repurposing an FDA-approved anti-gout drug for the treatment of COVID-19

Luo, Honglin | University of British Columbia | Project Grant | $562,275

CIHR British Columbia 2021

COVID-19 Variant Supplement – Contribution of genetic variation of ACE2, the receptor for SARS-CoV-2, to COVID‑19 disease expression and development of therapeutics

Haas, Kurt | University of British Columbia | Operating Grant | $50,000

CIHR British Columbia 2021

The Canadian COVID‑19 Funded Research Database

Advanced Keyword Search

Provinces & Territories (12)

Institutions (175)

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

Y

Years (4)

Funding Agencies (3)

Languages (2)

Funding Amount

All-cause and cause-specific acute morbidity attributable to Covid-19 epidemic, severe Covid-19 symptoms, and adverse birth outcomes in Canada.

COVID-19 Variant Supplement – Neutralizing human-derived single-chain antibodies against SARS-CoV-2

COVID-19 Variant Network – Bespoke transition state analog inhibitors of SARS-CoV-2 3CL and PL proteases

CATCO Scale-Up COVID‑19 Supplement – Canadian Treatments for COVID-19: SOLIDARITY

COVID-19 Variant Supplement – Assessing the impact of the COVID‑19 pandemic on social and health outcomes among young people: A mixed-method comparative analysis in Canada and France

Upstream determinants of effective COVID‑19 response: tools development and application through a case study in British Columbia

Enhancing culturally-safe ways for community wholistic health and wellness aspirations during COVID-19.

COVID-19 Variant Supplement – Peptide macrocycle decoys against COVID‑19 viral spike protein

Repurposing an FDA-approved anti-gout drug for the treatment of COVID-19

COVID-19 Variant Supplement – Contribution of genetic variation of ACE2, the receptor for SARS-CoV-2, to COVID‑19 disease expression and development of therapeutics